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Objectives: Asbestos-exposure causes an inflammatory response driven by alveolar macro-
phages that can lead to pulmonary fibrosis. In addition to classical inflammatory cytokines,
macrophages produce adipokines which regulate the inflammatory response. We studied if adi-
pokines are related to the degree of parenchymal fibrosis, impaired lung function and inflam-
mation in asbestos-exposed subjects.
Methods: Eighty-five males with moderate to heavy occupational exposure to asbestos and
unexposed controls were studied. We measured plasma levels of adipokines adiponectin, adip-
sin, leptin and resistin, IL-6, IL-8, erythrocyte sedimentation rate (ERS), spirometry and DL,CO.
Degree of interstitial lung fibrosis (septal thickening, subpleural lines, parenchymal bands or
honeycombing) was scored in classes 0e5 according to a validated scoring system. The subjects
were divided into three groups: normal parenchymal finding (fibrosis class 0), borderline
changes (classes 0.5e1.5) and fibrosis (i.e. asbestosis; classes 2e5).
Results: Adipsin correlated positively with parenchymal fibrosis (rhoZ 0.412, p< 0.001) and
there was a linear increasing trend of mean plasma adipsin levels among the three groups of
asbestos-exposed subjects (from normal parenchymal finding to borderline changes and to
fibrosis) (p< 0.0001). Accordingly, plasma adipsin levels correlated positively with the extent
of pleural plaques (rZ 0.245, pZ 0.043), and negatively with DL,CO (rZ0.246, pZ 0.023).
Also, a positive correlation was found between adipsin and inflammatory markers ESRof Respiratory Medicine, Tampere University Hospital, PL 2000, 33521 Tampere, Finland. Tel.: þ358 3
@uta.fi (S. Leivo-Korpela).
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1436 S. Leivo-Korpela et al.(rZ 0.315, pZ 0.008) and IL-6 (rZ 0.256, pZ 0.018).
Conclusions: Adipsin was associated with the degree of parenchymal fibrosis, impairment of
pulmonary diffusing capacity and with inflammatory activity in asbestos-exposed subjects sug-
gesting that adipsin may have a role in the pathogenesis or as a biomarker in asbestos-induced
lung disease.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Asbestosis is a diffuse interstitial lung fibrosis caused by an
inflammatory response to inhaled asbestos fibres.1 Alveolar
macrophages release various cytokines in response to
asbestos-exposure and they play a significant role in the
pathogenesis of interstitial fibrosis.2 The development of
asbestosis requires moderate or heavy exposure to asbestos
and takes 15e20 years in most cases. The detailed patho-
genesis of asbestosis is poorly known and further under-
standing of the disease mechanisms is required to lay the
background for the development of disease-modifying
treatments for asbestosis.
The diagnosis of asbestosis is based on findings of diffuse
interstitial fibrosis when a history of sufficient exposure to
asbestos exists and other causes of pulmonary fibrosis have
been ruled out.3 Diagnostic criteria for diffuse pulmonary
fibrosis in asbestos-exposed subjects are based on findings
on high-resolution computed tomography (HRCT) of the
lungs. However, only a part of asbestos-exposed subjects
develop diffuse pulmonary fibrosis, while many of the
subjects show either normal HRCT or only borderline
parenchymal changes that do not fulfil the diagnostic
criteria for asbestosis.4,5 According to the recent findings,
the borderline parenchymal changes are also associated
with increased pulmonary inflammation and they may be an
early stage of the process finally leading to frank fibrosis
and asbestosis.6 Further studies are needed to identify
biomarkers of asbestos-induced immunoresponse leading to
pulmonary fibrosis.
Adipokines like adiponectin, adipsin, leptin and resistin
are protein mediators first identified as products of adipose
tissue regulating energymetabolism and appetite. Recently,
adipokines have also been found to be produced by macro-
phages and various other cells and to regulate and mediate
inflammatory responses.7,8 Leptin and resistin are usually
pro-inflammatory, while adiponectin has mainly anti-
inflammatory properties.7,8 Adipsin is a rate-limiting
enzyme in the alternative complement cascade9 supporting
its function as a pro-inflammatory factor. There is increasing
evidence showing that adipokines play a role also in asthma
and COPD,10 but very little is known on adipokines in context
of other lung diseases. Recently, we reported that plasma
levels of adipsin, and to a lesser extent also those of resistin,
were clearly increased in workers with a history of heavy
occupational silica exposure suggesting a possible role for
adipokines also in parenchymal lung diseases.11 However,
there are no previous studies on the role of adipokines in
asbestos-induced lung diseases.
As asbestos-exposure causes an inflammatory response
in the lungs driven by alveolar macrophages and macro-
phages are known to secrete adipokines, we hypothesisedthat adipokines may be factors involved in asbestos-
induced lung inflammation and fibrosis. Therefore we
investigated if plasma levels of adipokines adiponectin,
adipsin, leptin or resistin are associated with pulmonary
fibrosis, impaired lung function or markers of inflammation
in asbestos-exposed subjects. The results show that adipsin
may be an important factor or biomarker in the develop-
ment of asbestosis because plasma adipsin levels were
associated with parenchymal fibrosis and pleural plaques,
with reduced diffusion capacity and with increased levels
of inflammatory markers ESR and IL-6.Methods
Subjects and study design
We recruited 118 men at the Clinic of Occupational Medicine
at Tampere University Hospital with moderate or heavy
occupational exposure to asbestos. To exclude other pulmo-
nary diseases that might affect the inflammatory markers,
the exclusion criteria were FEV1/FVC< 0.70, bronchiectasis
or any signs of emphysema on HRCT, diagnosed asthma, or
asthma medication. Twenty-eight healthy men with normal
spirometry, no respiratory symptoms and no known exposure
to asbestos or other harmful agents served as the control
group. All the subjects were never smokers or had quit
smoking for at least 5 years prior. The protocol was approved
by the Ethics Committee of Tampere University Hospital and
all the subjects gave their written informed consent.
Spirometry was measured and a venous blood sample
was drawn in all subjects. All the subjects in the exposed
groups had a history of moderate or heavy occupational
exposure to asbestos (estimation of at least 20 fibre years)
considered sufficient to cause asbestosis. HRCT of the lungs
was taken and pulmonary diffusing capacity for carbon
monoxide (DL,CO) was measured in asbestos-exposed
subjects, and they were divided into three groups based
on parenchymal findings on HRCT: (1) normal parenchymal
finding, (2) borderline parenchymal finding with minor
sporadic changes only, or (3) mild to extreme pulmonary
fibrosis (i.e. asbestosis), see Table 1.
Of the 118 asbestos-exposed men, 33 were excluded
based on the above mentioned exclusion criteria (16 due to
FEV1/FVC< 0.70, 11 due to emphysema or bronchiectasiae
on HRCT and 6 due to diagnosed asthma or use of asthma
medication) and 85 were included in the study. Of the 85
subjects included in the final analysis, 35 subjects had
normal parenchymal findings on HRCT (fibrosis class 0), 31
subjects had borderline parenchymal changes (fibrosis
classes 0.5e1.5), and 19 subjects had pulmonary fibrosis
(fibrosis classes 2.0) regarded as asbestosis.
Table 1 Criteria for parenchymal fibrosis and the classi-
fication system of fibrosis severity on high-resolution
computed tomography of the lungs. Modified from Huusko-
nen et al.4
Criteria for parenchymal
fibrosis
Septal thickening
Subpleural lines
Parenchymal bands
Honeycombing
Fibrosis classes
Class 0, normal
parenchymal finding
Normal finding by all
the criteria
Class 1, borderline
parenchymal changes
1e2 criteria sporadically
in the lung periphery;
no honeycombing
Class 2, mild fibrosis At least 2 criteria on both
sides and on several slices
in the lung periphery;
no honeycombing
Class 3, moderate fibrosis Several criteria, changes
extend deeper into the lung
than in class 2; honeycombing
as a general rule
Class 4, severe fibrosis Several criteria or associated
findings extending deep into
the lung; honeycombing;
lung architectural change
Class 5, extreme fibrosis Extremely severe and various
fibrotic changes; little
normally aerated lung left
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HRCT was scanned (Siemens Somatom Plus 4; Siemens
Medical, Erlangen, Germany) with 1 mm slices taken at
3 cm intervals using imaging parameters of 130e140 kV and
100e111 mA. The HRCT images were scored using
consensus reading by two experienced thoracic radiologists
(RJ and TV) blinded to the medical information of the
patients. Pulmonary fibrosis, emphysema, parietal pleural
plaques, and pulmonary nodules were scored separately as
described previously.4,12 The semi-quantitative scoring of
the HRCT findings indicating interstitial lung fibrosis (septal
thickening, subpleural lines, parenchymal bands or honey-
combing) in both lungs was made according to a scale of
classes from 0 to 5. Fibrosis class 0 represents normal
parenchymal finding, class 1 (0.5e1.5) represents border-
line parenchymal finding with minor sporadic changes, and
classes 2e5 represent mild to severe diffuse pulmonary
fibrosis (Table 1).4 If the readers could not match the
findings exactly with any given fibrosis class, five subclasses
(0.5, 1.5, 2.5, 3.5, 4.5) were used. The fibrosis class 2 has
been considered as a threshold for the diagnosis of
asbestosis.4
Adipokines and inflammatory markers
Venous blood was collected for the assessment of plasma
levels of adipokines (adiponectin, adipsin, leptin, resistin)
and serum levels of interleukin 6 (IL-6) interleukin 8 (IL-8),and blood erythrocyte sedimentation rate (ESR). Adipokines
were determined by enzyme-immuno-assay (EIA) by using
commercial reagents (DuoSet ELISA, R&D Systems Europe
Ltd, Abindgon, U.K). IL-6 and IL-8 were measured by
enzyme-linked immunosorbent-assay (PeliPair ELISA, San-
quin, Amsterdam, The Netherlands). The detection limits
and inter-assay coefficients of variation, respectively, were
15.6 ng/l and 2.4% for adiponectin, 4.0 ng/l and 1.8% for
adipsin, 15.6 ng/l and 1.9% for leptin, 15.6 ng/l and 7.3% for
resistin, 0.6 ng/l and 2.9% for IL-6, and 1.56 ng/l and 0.9%
for IL-8.
Statistics
The distribution of leptin levels was skewed while other
adipokines were normally distributed (Kolmogor-
oveSmirnov’s test). Differences in adipokine levels
between the subject groups were analysed using one-way
ANOVA with GameseHowell post-test (adiponectin, adip-
sin, resistin) or non-parametric KruskalleWallis ANOVA with
Dunn’s post-test (leptin). Skewed data are presented as
median [interquartile range] and normal data as mean -
 SEM. Pearson’s r was used to analyse the correlations
between adipsin or resistin and lung function or other
inflammatory markers. As adiponectin and leptin correlated
with BMI, partial correlations controlling for BMI were used
to analyse the correlations between adiponectin or leptin
and lung function or other inflammatory markers. Spear-
man’s rho was used to study correlations between fibrosis
class in the HRCT and adipokines. A p-value <0.05 was
considered as significant. SPSS 15.0.1 (SPSS Inc., Chicago,
Illinois, USA) and InStat 3.05 (GraphPad Software, Inc., San
Diego, CA, USA) softwares were used in the statistical
analysis.
Results
Subject characteristics, indices of pulmonary function and
levels of inflammatory markers are given in Table 2. Among
the asbestos-exposed subjects, FVC % predicted
(pZ 0.051), FEV1 % predicted (pZ 0.022) and DL,CO %
predicted (p< 0.001) were lower while the extent of
pleural plaques (pZ 0.066) was higher in subjects with
parenchymal fibrosis than in subjects with normal paren-
chymal finding on HRCT.
Adipsin, but no other adipokines, correlated positively
with the degree of parenchymal fibrosis: Spearman’s rho for
the correlation between plasma adipsin and fibrosis class
determined on HRCT (classes 0e5) was 0.412 (p< 0.001).
There was also a statistically significant (p< 0.0001)
increasing linear trend in serum adipsin levels when the
asbestos-exposed subjects were divided into three groups,
i.e. subjects with normal finding, borderline finding or
fibrosis in HRCT (Fig. 1). Accordingly, adipsin levels were
higher in asbestos-exposed subjects with pulmonary fibrosis
as compared to exposed subjects with no parenchymal
fibrosis (pZ 0.013) or to unexposed control subjects
(pZ 0.038).
In support to the association of adipsin with the severity
of asbestos-induced lung reaction, plasma adipsin levels
were found to correlate positively with the extent of
Table 2 Subject characteristics.
No fibrosis Borderline fibrosis Fibrotic (asbestosis) Unexposed, healthy controls
N 35 31 19 28
Age (yrs) 62 1 67 1 68 1 62 1
BMI (kg/m2) 30 1 29 1 27 1 27 1
FEV1(% pred) 92 2 85 3 82 3 *
FVC (% pred) 92 3 85 3 84 3 *
Hb-DL,CO (% pred) 109 2 98 3 86 4 N.A.
ESR (mm/h) 10 1 10 1 14 5 N.A.
IL-6 (ng/l) 3.5 0.3 4.5 0.6 3.7 0.5 2.6 0.4
IL-8 (ng/l) 10.6 0.7 11.6 1.4 8.2 1.3 10.2 0.6
Adipsin (ng/ml) 871 32 965 34 1129 70 906 34
Adiponectin (ng/ml) 2212 149 2727 202 2969 256 2360 169
Leptin (ng/ml) 8.2 [5.6 e13.6] 6.9 [5.3e10.5] 7.5 [6.7e9.7] 5.6 [1.7e8.9]
Resistin (ng/ml) 17.2 1 19.1 1 14.9 1 19.1 1
Pleural plaques (cm2) 286 24 362 22 490 65 N.A.
Values are presented as mean SEM for normal data and as median [interquartile range] for non-normal data.
*, Normal in every subject; and N.A., not analysed.
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; Hb-DL,CO, pulmonary diffusing capacity for
carbon monoxide standardized for hemoglobin; ESR, erythrocyte sedimentation rate; IL-6, interleukin 6; and IL-8, interleukin 8.
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(rZ 0.245, pZ 0.043, Table 3) and negatively with
pulmonary diffusing capacity (DL,CO) (rZ0.246,
pZ 0.023, Fig. 2), i.e. the higher the adipsin level the
poorer the diffusing capacity and the more pleural plaques.
Interestingly, plasma adipsin concentrations correlated also
with ESR (rZ 0.315, pZ 0.008, Fig. 2) and with plasma IL-6
(rZ 0.256, pZ 0.018, Table 3) showing an association with
the asbestos-induced inflammation.Figure 1 Plasma adipsin levels in asbestos-exposed subjects
with normal, borderline or fibrotic (i.e. asbestosis) paren-
chymal findings on HRCT, and in unexposed controls.There were no significant differences in adiponectin,
leptin or resistin levels between the groups. A positive
correlation was found between resistin and IL-6 levels but
adiponectin or leptin did not correlate significantly with
lung function, pleural plaques or the inflammatory markers
measured in blood.
Discussion
The main finding in the present study was that plasma
levels of adipsin were associated with the degree of
parenchymal fibrosis, with impairment of pulmonary
diffusing capacity, with the extent of pleural plaques and
with the systemic markers of inflammation in asbestos-
exposed subjects. This suggests that adipsin may have
a role in the pathogenesis of asbestos-induced lung injury.
The pathogenesis of asbestos-induced diseases is asso-
ciated with persistent inflammatory response to asbestos
with cellular and immunological abnormalities.1 Asbestosis
is characterized by slowly progressing interstitial fibrosis in
alveolar wall and increased numbers of activated alveolar
macrophages.13 Alveolar macrophages secrete IL-614 that
stimulate fibroblast proliferation.13 Macrophages also
secrete adipokines7 that are known to be associated with
other inflammatory lung diseases like asthma and COPD.10
This is the first study to show an association between adi-
pokine adipsin and inflammatory activity and degree of
fibrosis in asbestos-exposed subjects. Adipsin may thus be
a factor in the pathogenesis of asbestosis and the present
results encourage future studies to identify the potential
role of adipsin in the disease mechanisms as well as
a possible treatment target. That is of particular interest
because the pathogenesis of asbestos-induced inflamma-
tory response leading to lung fibrosis is not understood in
detail and because of the lack of disease-modifying treat-
ments for asbestosis.
Based on the present results, adipsin may also have
a value as a biomarker of the inflammatory activity and/or
Table 3 Correlations between plasma adipokines and other parameters in asbestos-exposed subjects (nZ 85).
Adiponectina Adipsin Leptina Resistin
FVC (% pred) rZ0.082 rZ0.163 rZ0.246 rZ 0.115
pZ 0.521 pZ 0.142 pZ 0.050 pZ 0.300
Hb-DL,CO (% pred) rZ0.029 rZ0.246 rZ0.195 rZ0.058
pZ 0.818 pZ 0.023 pZ 0.122 pZ 0.599
Pleural plaques (cm2) rZ0.028 rZ 0.245 rZ 0.019 rZ 0.088
pZ 0.825 pZ 0.043 pZ 0.884 pZ 0.473
ESR (mm/h) rZ 0.018 rZ 0.315 rZ 0.243 rZ 0.102
pZ 0.886 pZ 0.008 pZ 0.053 pZ 0.399
IL-6 (ng/l) rZ0.146 rZ 0.256 rZ 0.157 rZ 0.291
pZ 0.251 pZ 0.018 pZ 0.214 pZ 0.007
IL-8 (ng/l) rZ0170 rZ0.049 rZ 0.140 rZ 0.047
pZ 0.180 pZ 0.655 pZ 0.272 pZ 0.670
FVC, forced vital capacity; Hb-DL,CO, pulmonary diffusing capacity for carbon monoxide standardized for hemoglobin; ESR, erythrocyte
sedimentation rate; IL-6, interleukin 6; and IL-8, interleukin 8.
p-value < 0.05 was considered as significant.
a Because adiponectin and leptin correlated with BMI, partial correlations controlling for BMI were calculated.
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There is a clinical need for biomarkers showing the current
activity of asbestos-induced immune response to predict
the individual risk for development or further progression
of pulmonary fibrosis. We and others have previously
reported some promising markers in exhaled air or sputum
to be associated with asbestos-induced lung injury,6,15e17
but there are no previous studies on the role of adipo-
kines in asbestos-induced lung diseases. The present results
do, however, encourage a follow-up study to investigate if
adipsin might have a predictive value in assessing the rate
of the fibrosing process or the risk to develop asbestosis at
individual patient level.
Adipsin is also known as complement factor D, which is
a rate-limiting enzyme in the alternative pathway of
complement activation.9 Adipsin, together with other
components of the complement cascade, is primarily
expressed in adipocytes and monocyte-macrophages in
human subjects.9 There are only a few previous studies on
adipsin in respiratory diseases. Increased plasma adipsin
levels have been found in males with seasonal allergic
rhinitis,18 and adipsin has been associated with an experi-
mental model of pulmonary hypertension.19 Our presentFigure 2 Plasma adipsin levels correlated positively with erythro
diffusing capacity for carbon monoxide (DL,CO) in asbestos-exposedresults suggest that adipsin might act as a pro-inflammatory
molecule in asbestos-induced lung injury as adipsin levels
correlated positively with IL-6 and ESR and were associated
with the degree of interstitial lung fibrosis. This would be in
line with the fact that alveolar macrophages have a key role
in the pathogenesis of asbestosis20 and macrophages are an
important source of adipsin.9 However, adipsin could also
be merely a marker of activation of alveolar macrophages
and further studies are needed to elucidate whether or not
adipsin has a true pathogenetic role in asbestosis. Based on
the present results it is not clear whether adipsin is
specifically associated with asbestos related macrophage
activation or is it also associated with other forms of
fibrosing lung diseases. The latter assumption is supported
by our previous finding of increased plasma adipsin levels in
subjects with heavy occupational exposure to silica.11
However, further studies are needed to clarify if other
forms of interstitial lung diseases or current cigarette
smoking activating pulmonary macrophages could also
affect the adipsin levels.
Adipocytes are the most important source of adiponectin
and leptin7 and circulating leptin levels correlate with
adipose tissue mass.21 Adiponectin appears to act as an anti-cyte sedimentation rate (ESR) and negatively with pulmonary
subjects (nZ 85).
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inflammation22 andprotects against asthma.23 Leptin is a pro-
inflammatorymolecule and high leptin levels are a risk factor
for asthma independent of BMI.24 However, the present study
did not find any relation between adiponectin or leptin and
asbestos-induced lung disease. Resistin is produced by
adipocytes and macrophages and it is associated with
inflammatory states, but its role is not very well understood.8
In asthma, resistin has been reported to be positively corre-
lated with the disease severity25 and we have recently found
resistin to predict favourable anti-inflammatory response to
inhaled glucocorticoids in asthma.26 However, the current
results suggest that resistin does not have a significant role in
asbestos-induced lung disease.
In the present study adipokine adipsin was found to be
associated with the degree of pulmonary fibrosis and
systemic markers of inflammation in asbestos-exposed
workers. Thus, adipsin may have a role in the pathogen-
esis or as a biomarker in asbestos-induced lung diseases.
Further studies are needed to elucidate if adipsin could be
used as a prognostic tool in the follow-up of asbestos-
exposed workers.
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